Merck Tackles Patent Cliff with Keytruda Combo Trial

Merck is taking steps to ensure its flagship immunotherapy drug Keytruda remains competitive as its patent begins to expire. The company plans to conduct a sac-TMT combo trial with Keytruda, according to recent announcements.

The move comes as Merck's patent for Keytruda starts to wear off, raising concerns about the drug's market share and revenue. Keytruda has been one of Merck's top-selling products, but its exclusivity will soon come to an end.

Merck CEO Rob Davis emphasized the company's commitment to expanding its oncology portfolio in response to the patent cliff. By combining Keytruda with other treatments, Merck aims to maintain market share and drive growth despite the looming patent expiration.